{"product_id":"orasure-five-forces-analysis","title":"OraSure Technologies Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOraSure Technologies faces mixed pressure: strong buyer scrutiny in diagnostics, moderate supplier leverage, high regulatory and reimbursement barriers limiting new entrants, and rising substitutes from at-home and lab-based tests tightening margins.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore OraSure Technologies’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure depends on medical-grade chemical reagents and biological components for its point-of-care tests, with fewer than 10 certified global suppliers for key inputs as of 2025, raising supplier bargaining power.\u003c\/p\u003e\n\u003cp\u003eStrict FDA and CE regulatory specs limit vendor pool, so suppliers can push prices; in 2024 reagent cost volatility spiked 18%, squeezing gross margins by an estimated 120–180 basis points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Manufacturing Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure relies on specialized automated molding and specimen-device lines, many custom-built or serviced by a handful of engineering firms, giving suppliers leverage; in 2024 OraSure spent ~ $18m on contract equipment maintenance and capital spare parts, about 4% of revenue, limiting quick vendor swaps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers in diagnostics must meet ISO 13485 and FDA QSR standards; for OraSure Technologies (NASDAQ: OSUR) this means supplier qualification ties into regulatory filings, making vendor changes slow and costly.\u003c\/p\u003e\n\u003cp\u003eQualifying a new supplier can take 6–18 months and cost hundreds of thousands of dollars in validation and regulatory submissions, creating supplier lock-in.\u003c\/p\u003e\n\u003cp\u003eThat lock-in lets key suppliers sustain higher margins, raising OraSure’s supplier bargaining power and operating risk if single-source inputs fail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCold-chain needs for OraSure’s molecular collection kits and certain diagnostics make specialized logistics providers critical; global cold-chain market grew 10.8% in 2024 to $23.4B, concentrating pricing power in niche carriers.\u003c\/p\u003e\n\u003cp\u003eValidated temperature control prevents spoilage and regulatory rejects, so a 15–25% freight price spike or a 3–7 day disruption can cut margins and delay deliveries for time-sensitive SKUs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized carriers concentrated: high bargaining power\u003c\/li\u003e\n\u003cli\u003e2024 cold-chain market $23.4B, +10.8% YoY\u003c\/li\u003e\n\u003cli\u003ePrice shocks (15–25%) directly hit margins\u003c\/li\u003e\n\u003cli\u003e3–7 day delays risk regulatory loss or spoilage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property of Biological Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure often needs licensed antibodies or genetic sequences owned by biotech firms to develop assays; these licensors can demand high fees or restrictive terms because their IP is essential and hard to substitute.\u003c\/p\u003e\n\u003cp\u003eIn 2024, licensing deals for proprietary reagents averaged royalty rates of 3–8% of product sales and upfront payments of $0.5–$5M, pressuring margin for niche infectious-disease kits.\u003c\/p\u003e\n\u003cp\u003eNegotiation leverage rises when a single supplier holds key patents—OraSure may face longer lead times, exclusivity constraints, or milestone payments that raise COGS and slow product rollout.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003cli\u003eKey fact: 3–8% typical royalty; $0.5–$5M upfront (2024 deals)\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: \u0026lt;10 certified vendors, +18% reagent volatility, 120–180bps margin hit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: \u003cbr\u003efew (\u0026lt;10) certified reagent suppliers (2025), 6–18 months to qualify new vendors, 2024 reagent cost volatility +18% (120–180 bps margin hit), 2024 cold-chain market $23.4B (+10.8%), specialty equipment\/maintenance ~$18M (≈4% revenue, 2024), licensing royalties 3–8% with $0.5–$5M upfront (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified suppliers\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent volatility\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin impact\u003c\/td\u003e\n\u003ctd\u003e120–180 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain market\u003c\/td\u003e\n\u003ctd\u003e$23.4B (+10.8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment spend\u003c\/td\u003e\n\u003ctd\u003e$18M (~4% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e3–8% royalty; $0.5–$5M upfront\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for OraSure Technologies, this Porter's Five Forces overview uncovers competitive drivers, buyer\/supplier influence, entry barriers, substitutes, and disruptive threats shaping its market positioning and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet for OraSure Technologies—quickly spot competitive pressures and strategic levers to relieve pain points in diagnostics and bioscience markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment and public health procurement accounts for roughly 40–55% of OraSure Technologies’ revenue during pandemic peak years, with major buyers like the US CDC and WHO-funded programs buying in bulk.\u003c\/p\u003e\n\u003cp\u003eThese buyers wield high bargaining power via competitive bidding and framework contracts, pushing prices down and imposing strict compliance terms.\u003c\/p\u003e\n\u003cp\u003eOraSure often concedes lower gross margins—reported at ~20–25% on contract segments—to secure multi-year, high-volume orders and predictable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy and Wholesale Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge retail chains like cvs health sales pharmacy segment and national distributors such as mckesson revenue act gatekeepers to otc home tests controlling shelf placement pricing for orasure kits. if a major distributor favors rival would lose immediate visibility shopper access which can cut by double-digit percentages merchandising shifts have driven volume swings in comparable categories. this concentration raises bargaining power buyers increases distribution risk.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Individual Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn the over-the-counter market, consumers treat rapid diagnostic tests as commodities where price drives choice, so OraSure faces weak customer pricing power and fragile brand loyalty. With negligible switching costs for HIV or COVID-19 tests, many buyers shift to lower-priced rivals; US OTC antigen market saw price-sensitive volume growth of 18% in 2024. This dynamic forces OraSure to spend heavily on marketing—company SG\u0026amp;A rose 12% in FY2024—to maintain share and deter migration to cheaper alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth System and Hospital Network Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs US hospital systems consolidated—top 25 systems accounted for ~40% of admissions in 2024—large buyers extract double-digit discounts on diagnostics, pressuring OraSure’s margins.\u003c\/p\u003e\n\u003cp\u003eProcurement teams use competitive bids and 3–5 year contract cycles to pit manufacturers against each other, forcing OraSure to prove cost-per-test and ROI.\u003c\/p\u003e\n\u003cp\u003eOraSure needs robust clinical data (peer-reviewed sensitivity\/specificity \u0026gt;95% where applicable) plus integrated training, EHR integration, and service SLAs to defend pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop 25 systems = ~40% admissions (2024)\u003c\/li\u003e\n\u003cli\u003eContracts often 3–5 years; discounts commonly 10–30%\u003c\/li\u003e\n\u003cli\u003eClinical data \u0026gt;95% sensitivity\/specificity boosts win rate\u003c\/li\u003e\n\u003cli\u003eOffer EHR integration + training + SLAs to retain accounts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedicare and private insurers set reimbursement rates that effectively cap what OraSure Technologies can charge for point-of-care tests; lower payer rates shift costs to patients and reduce demand. In 2024 Medicare reimbursement cuts averaged 3.5% for certain outpatient diagnostics, showing how payer decisions directly pressure pricing and volumes. Third-party payers therefore act as proxies for customer bargaining power by limiting OraSure’s achievable net price.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare\/private rates cap effective price\u003c\/li\u003e\n\u003cli\u003e2024 Medicare diagnostic cuts ~3.5%\u003c\/li\u003e\n\u003cli\u003eReduced coverage shifts cost to patients, lowering demand\u003c\/li\u003e\n\u003cli\u003ePayers function as surrogate customer leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers Dictate Deep Discounts, Capped Prices, and Tight SLAs for OraSure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (governments, large retailers, hospital systems, payers) have high bargaining power, driving 10–30% contract discounts, capping net prices via reimbursement cuts (~3.5% Medicare 2024), and forcing OraSure to accept lower ~20–25% margins on bulk contracts; OraSure must supply \u0026gt;95% sensitivity data, EHR integration, training, and SLAs to win multi-year (3–5 yr) deals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt\/NGO\u003c\/td\u003e\n\u003ctd\u003eBulk contracts\u003c\/td\u003e\n\u003ctd\u003e40–55% rev (pandemic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/Dist\u003c\/td\u003e\n\u003ctd\u003eShelf access\u003c\/td\u003e\n\u003ctd\u003e10–30% vol swing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Payers\u003c\/td\u003e\n\u003ctd\u003ePrice caps\u003c\/td\u003e\n\u003ctd\u003e10–30% discounts; 3.5% Medicare cut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eOraSure Technologies Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of OraSure Technologies you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the same professionally written, fully formatted file you'll be able to download and use the moment you buy, covering supplier power, buyer power, competitive rivalry, threat of substitutes, and barriers to entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747056955769,"sku":"orasure-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/orasure-five-forces-analysis.png?v=1772194690","url":"https:\/\/matrixbcg.com\/products\/orasure-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}